The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of EGFR inhibition with cetuximab (CET) on the efficacy of paclitaxel (TAX) in previously treated metastatic (MET) urothelial cancer.
Y. Wong
Consultant or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb (U)
Research Funding - Bristol-Myers Squibb
S. Litwin
No relevant relationships to disclose
D. J. Vaughn
No relevant relationships to disclose
E. R. Plimack
No relevant relationships to disclose
W. Song
No relevant relationships to disclose
J. W. Lee
No relevant relationships to disclose
M. B. Dabrow
No relevant relationships to disclose
M. Brody
No relevant relationships to disclose
H. Tuttle
No relevant relationships to disclose
G. R. Hudes
Consultant or Advisory Role - Bristol-Myers Squibb (U)